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Abstract
Background: No consensus exists on the outcome-related factors of interval debulking surgery (IDS) in patients
with advanced high-grade serous ovarian cancer (HG-SOC) who underwent neoadjuvant chemotherapy (NAC). This
study aimed to explore the optimal timing for IDS and the prognosis-associated factors of International Federation
of Gynecology and Obstetrics stage IIIc to IV HG-SOC patients.
Methods: A total of 160 IIIc to IV stage HG-SOC patients were retrospectively analyzed. Patients with large volume
ascites underwent NAC and subsequent IDS from the Jiangsu Institute of Cancer Research between 1993 and 2013.
The outcome of IDS-associated factors was explored by logistic regression. To predict IDS outcome, the potential
values of serum CA-125 levels and CA-125 decreasing kinetics were determined by the receiver operating
characteristic curve. The associations between survival durations and covariates were assessed by Cox proportional
hazards model and log-rank test.
Results: Optimal IDS was achieved in 80.6% of HG-SOC patients who underwent NAC. Multivariate analyses
revealed that ascites regression (p = 0.01), serum CA-125 level (p = 0.02), and CA-125 decreasing kinetics (p = 0.01)
were independent optimal IDS predictors. CA-125 decreasing kinetics, IDS outcome, and ascites volume were
independently associated with overall survival (OS) (p = 0.04, p < 0.01, p = 0.03, respectively) and progression-free
survival (PFS) (p < 0.01, p < 0.01, p = 0.02, respectively). Patients who exhibited disappearance of ascites (<500 ml)
had longer PFS (19.7 months vs.14.9 months) and OS (32.1 months vs. 26.0 months) than patients who exhibited
residual ascites (≥500 ml). Subsets with higher CA-125 decreasing kinetics (≥2.2) had longer PFS (21.4 months vs.13.
1 months) and OS (29.6 months vs.26.8 months) than counterparts (kinetics < 2.2).
Conclusions: Ascites regression and CA-125 decreasing kinetics were independently associated with surgical
outcome and prognosis in advanced HG-SOC patients who underwent NAC.
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Background
Epithelial ovarian cancer (EOC) is the most lethal
gynecological cancer in North America, Western
Europe, and China [1, 2]; its mortality rate has insignifi-
cantly decreased since the 1970s [3]. A total of 41,516
EOC cases were registered in China in 2011[4]. In 2015,
EOC resulted in an estimated 21,290 cases and 14,180
deaths in the United States [5].
EOC is a heterogeneous tumor group, with high-grade
serous ovarian cancer (HG-SOC) as the archetype and
main cause of the high fatality rate [6]. The treatment
outcome of HG-SOC is very poor because this disease is
most commonly diagnosed in advanced stages at initial
treatment. The current standard therapeutic strategy for
advanced ovarian cancer is maximum primary debulking
surgery (PDS) followed by frontline taxane plus carbo-
platin chemotherapy. Cytoreduction aims to achieve op-
timal debulking, as the amount of residual tumor after
this procedure is one of the most important prognostic
factors for the survival of women with HG-SOC. Over
the past 30 years, the definition of optimal cytoreduction
has changed from residual tumors <1–2 cm to absent
macroscopic disease [7–11].
An optimal surgical procedure is not always possible for
patients with advanced-stage HG-SOC (IIIc to IV) with
poor performance status or medical contraindications.
Morever, extensive internal organ resection and major
blood loss are associated with a high risk of morbidity. To
reduce the patient’s tumor burden and improve thera-
peutic effect by allowing further surgery, surgeons investi-
gated the possibility of reducing tumor size with two to
four cycles of neoadjuvant chemotherapy (NAC). No con-
sensus exists on the optimal timing indicators for interval
cytoreduction surgery (IDS) in advanced ovarian cancer,
including tumor markers, ascites volume, imaging infor-
mation, and patients’ status [12, 13].
Women who have a high perioperative risk profile or a
low likelihood of achieving cytoreduction to <1 cm
(ideally to no visible disease) were suggested to receive
NAC. Chemotherapy may increase the ratio of patients
suitable for IDS; the rates of optimal resection in IDS
after induction chemotherapy had been reported to
range from 77 to 94% [14–19]. Patients who underwent
IDS after NAC had lower morbidity, lower requirement
of intensive care unit admission, lower duration of hos-
pital stay, and higher quality of life than the patients
who underwent PDS.
A consensus exists that a complete resection of all
macroscopic disease (at PDS or IDS) is an independent
predictor of progression-free survival (PFS) and overall
survival (OS). Unlike the advantages for resectability and
response rates demonstrated by most studies, there is no
evidence of survival advantage demonstrating that NAC
followed by IDS is inferior to the gold standard
procedure, and the role of NAC has been debated for
years [20, 21]. Different EOC subtypes have distinct clin-
ical characteristics and prognosis [6, 22–25]. Further-
more, different research methods utilized distinct
recruitment standards that varied from one to another
in terms of ascites volume, gross tumor burden, and the
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(FIGO) stage. No published comparative study currently
exists on these issues in HG-SOC. Therefore, evaluating
the value of platinum-based NAC in a large HG-SOC
sub-population is urgently needed.
In the present study, we retrospectively analyzed clini-
copathological factors in patients with HG-SOC who re-




A retrospective chart review was conducted to identify
all patients diagnosed with HG-SOC treated at the JICR
from January 1, 1993 to December 31, 2013. The ana-
lysis included all the patients treated at the institution
during that period and who met the recruitment
standards.
Multidisciplinary team (MDT) consists of two gyneco-
logic oncologists, two pathologists, one radiologist and
one medical oncologist was set to indentify women with
a high perioperative risk profile or a low likelihood of
achieving optimal cytoreduction should receive NAC.
Before NAC is delivered, 76 patients have histologic con-
firmation of an invasive ovarian, fallopian tube, or peri-
toneal cancer from core biopsy. In exceptional cases,
when a biopsy cannot be performed, cytologic evaluation
combined with a serum CA-125 to carcinoembryonic
antigen (CEA) ratio >25 is acceptable to confirm the pri-
mary diagnosis in 62 cases. In other 22 cases with CA-
125 to CEA ratio was 25 or lower, patients had to have
an additional barium enema or colonoscopy, gastroscopy
or radiologic examination of the stomach, and mam-
mography to rule out a potential metastatic primary ma-
lignancy. Under these criteria, the incidence of other
malignancies confirmed by IDS was 5%; and only 8 pa-
tients were excluded in further analysis.
The recruit criteria of the present study were as fol-
lows: patients must be histological confirmed stage IIIc
to IV ovarian, fallopian tube, or peritoneal high-grade
serous cancer by IDS; An additional inclusion criterion
of large volume ascites estimated by ultrasound and con-
firmed by surgical procedure was set to observe the re-
gression of ascites by NAC (35 frailty cases underwent
slow-release evacuation procedure before NAC treat-
ment for the intolerable abdominal distension were ex-
cluded); patients who underwent PDS were excluded;
patients who underwent non-platinum NAC were
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excluded; patients who did not undergo entire primary
therapy procedure were excluded; patients with pre-
operative serum CA-125 levels < = 35 U/ml were ex-
cluded; laparoscopic proved HG-SOCs were excluded.
The number of NAC cycles was administered based on
the MDT’s decision. During 1993–1997, cisplatin
(50 mg/m2), farmorubicin (50 mg/m2), and a cyclophos-
phamide (500 mg/m2) combined regime was adminis-
trated to 18 HG-SOCs every 3 weeks. After 1997, 142
cases underwent carboplatinum (area under the curve
5–6) and paclitaxel (135–175 mg/m2) regime every
3 weeks. An IDS was scheduled approximately 2 to
4 weeks after NAC. Patients were then treated with at
least three to four additional chemotherapy cycles with
the same regimen as NAC. Disease progression was eval-
uated by computed tomography (CT, all cases)/magnetic
resonance imaging (MRI, 49 cases) or positron emission
tomography imaging (PET/CT, 25 cases) of the abdomen
and pelvis before initiating of frontline or second-line
chemotherapy. The patients’ follow-up plan after the
completion of primary treatment included clinical as-
sessment and serum marker measurement, as mentioned
previously [22–24].
Clinicopathological characteristics
The clinicopathological data of the patients were
reviewed and the following data were collected: age;
tumor grade; histology; tumor stage; serum CA-125 and
CEA levels during diagnosis, therapy, and follow-up;
NAC regime, courses, and clinical or pathological re-
sponses; optimality of cytoreductive surgery; and disease
status at the last follow-up. Ascites volume was estimated
by ultrasound and confirmed by surgical procedure. Re-
gression was defined by as an ascites volume < 500 ml.
CA-125 decreasing kinetics was defined as the ratio of the
initial serum CA-125 level divided by the preoperative
serum CA-125 level. Surgical staging followed the FIGO
system. Optimal cytoreduction was defined as the absence
of macroscopic disease on the completion of the surgical
procedure.
OS was defined as the length of time from diagnosis
to death, or to the last follow-up examination of patients
who are still alive. PFS was defined as the time interval
from primary treatment where in the patient’s condition
did not worsen. Clinical response of administration, in-
cluding NAC, IDS, and adjuvant chemotherapy, was de-
fined according to the standards of the Response
Evaluation Criteria in Solid Tumors [26]. The pathology
of all patients was initially reviewed by pathologists from
JICR (Hou and Xu). A panel of pathologic markers was
routinely measured. This study was approved by the eth-
ics committee of the Jiangsu Institute of Cancer Re-
search. Informed consent was obtained from all involved
participants.
Statistical analysis
The association between survival and adjuvant chemo-
therapy regime, courses, and therapy response was
assessed by the Cox proportional hazards model. The
multivariate model was constructed by step-wise regres-
sion techniques. P-values of less than 0.05 were consid-
ered to be significant. Survival distributions were
estimated by the Kaplan-Meier method, and statistical
significance was determined by log-rank test and Cox’s
proportional hazard model analysis. Optimal IDS-related
potential factors were explored by logistic regression
analysis. All data manipulation and statistical analysis
were performed by SPSS software v16 (SPSS for
Windows, Rel.16. Chicago: SPSS Inc.).
Results
Patient characteristics
Among the 382 patients with advanced stage HG-
SOC with large volume of ascites underwent entire
primary therapy procedure in JICR, 160 (41.9%)
patients received NAC and IDS, meeting the study
criteria; 129 (80.1%) patients received subsequent
optimal debulking surgery; and 31 patients received
suboptimal debulking surgery (macroscopic residual
disease). The median number of NAC cycles was 3
(range, 2 to 4). The clinicopathological characteristics of
recruited cases are described in Table 1. The median
follow-up duration of the survivors was 45 months (inter-
quartile range, 38.2 to 56.4 months).
Table 1 Patient characteristics of the study population
Characteristic Median Percentage/range
Age (years) 62.2 36–82
Initial CA-125 level (U/mL) 920 41–24440
CA-125 decreasing kinetics 2.2 0.9–28.6
Tumor sites a
< = 3 38 23.7%
> 3 122 76.3%
Preoperative ascites
< 500 ml 88 55.0%
> =500 ml 72 45.0%
Surgical residual
No macroscopic focus 129 80.6%
1–2 cm 6 3.8%





Tumor sites a abdomen is divided into four quadrants according to the
belly button
FIGO b the International Federation of Gynecology and Obstetrics
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Predictors of optimal IDS
The optimal IDS subset had a median preoperative
serum CA-125 level of 445 U/mL (range, 45–730 U/mL)
and CA-125 decreasing kinetics of 2.8. The suboptimal
IDS group had a median preoperative serum CA-125 of
653 U/mL (range, 41–980 U/mL) and CA-125 decreas-
ing kinetics of 1.7.
Univariate logistic regression analysis revealed that as-
cites regression, serum CA-125 level and decreasing kin-
etics, tumor sites, and patient’s age and status were IDS
outcome-related factors (Table 2). Furthermore, we
found that ascites regression (p = 0.01), preoperative
serum CA-125 level (p = 0.02), and CA-125 decreasing
kinetics (p = 0.01) were independent optimal IDS predic-
tors in multivariate analyses (Table 2). Analysis with the
receiver operating characteristic (ROC) curve revealed
that CA-125 decreasing kinetics (p = 0.02) and preopera-
tive ascites volume (p < 0.01) might imply optimal IDS
(Fig. 1a and b).
Ascites regression was associated with prognosis
Using the univariate Cox proportional hazards model,
we found that OS and PFS were associated with IDS
outcome (p < 0.01 and p < 0.01, respectively), preopera-
tive serum CA-125 level (p = 0.02 and p = 0.04, respect-
ively), CA-125 decreasing kinetics (p < 0.01 and p < 0.01,
respectively), and ascites volume (p < 0.01 and p < 0.01,
respectively) as shown in Table 3. Multivariate analysis
revealed that OS and PFS were independently associated
with CA-125 decreasing kinetics (p = 0.04 and p < 0.01,
respectively), IDS outcome (p < 0.01 and p < 0.01, re-
spectively), and ascite volume (p = 0.03 and p = 0.02,
respectively) as shown in Table 3.
Ascites regression indicated longer OS durations
(32.1 months, 95% confidence interval [CI] 27.1–37.1 vs.
26.0 months, [CI] 22.3–29.6, Fig. 2a) and PFS
(19.7 months, [CI] 17.8–21.6 vs. 14.9 months, [CI] 12.5–
17.2, Fig. 2b) for patients who underwent IDS. We set
the cut-off point at 2.2 for CA-125 decreasing kinetics.
Groups with higher CA-125 decreasing kinetics had
higher OS (29.6 months, [CI] 26.1–33.0 vs. 26.8 months,
[CI] 22.7–30.1) and PFS (21.4 months, [CI] 18.6–24.2
vs. 13.1 months, [CI] 10.8–15.5) durations than
groups with lower CA-125 decreasing kinetics (Fig. 3a
and b).
Discussion
Ovarian cancer is not a single disease entity, but rather
comprises a heterogeneous group of tumors with dis-
tinct clinicopathological characteristics. Inconsistent out-
comes regarding the prognostic significance of NAC
may be related to the failure to consider tumor grade,
histotype, stage, and chemotherapy response [27–32]. In
the current study, we identified optimal IDS and
prognosis-related factors in advanced HG-EOC patients
who underwent NAC.
We suggested that patient stratification by ascites re-
gression may be useful in analyzing the surgical timing
of NAC in advanced HG-EOC. Based on our previous
analysis [22–24], we assumed that CA-125 decreasing
kinetics implied NAC response and followed IDS out-
comes. Stratification by serum CA-125 level and CA-125
decreasing kinetics revealed that NAC group patients
with preoperative serum CA-125 levels <450 U/ml and
decreasing kinetics >2.2 significantly benefited in PFS
and OS. This result implied that only selected patients,
such as patients with HG-SOC and higher serum CA-
125 levels and drastically reduced CA-125 kinetics, may
receive survival benefit from NAC. Our data also sug-
gested that biomarkers or other prediction models may
be applied to identify target groups that can benefit from
NAC. The most intriguing feature of the current data is
the trend of the NAC hazard ratio according to the
spectrum of preoperative ascites volume. Patients with a
large amount of ascites had significantly poorer IDS out-
comes compared with patients who exhibited ascites re-
gression. This result suggests that NAC provides
superior IDS outcome in a select subset of patients.
In the present cohort, optimal IDS rate was signifi-
cantly higher in patients with CA-125 decreasing kinet-
ics higher than 2.2 or ascites regression. Therefore, it
was naturally expected that the improved optimal resec-
tion rate by NAC resulted in improved survival out-
come. Reports had repeatedly stated that the improved
optimal debulking rate obtained by NAC/IDS cannot
directly translate into increased PFS or OS compared
with PDS [33–36]. Although chemotherapy-assisted op-
timal cytoreduction is not biologically equivalent to opti-
mal surgic al debulking, NAC also aims to increase the
optimal resection rate. Our data proved that the patient
subset exhibiting ascites regression had as uperior opti-
mal resection rate. Therefore, ascites regression should
be regarded as a timing indicator for IDS. Ascites regres-
sion may be associated with histotype, chemotherapy
Table 2 Logistic regression of optimal IDS associated factors in
advanced HG-SOCs
Factors Univariate Multivariate
Exp(β) Sig Exp(β) Sig
Age 1.01 0.15 1.00 0.52
Ascites 1.90 0.01 2.20 0.01
Stage 1.4 0.30 1.33 0.18
Tumor sites 1.3 0.22 1.16 0.47
Baseline CA-125 1.13 0.01 1.08 0.35
Preoperative CA-125 1.28 0.00 1.05 0.02
CA-125 decreasing kinetics 2.15 0.01 2.40 0.01
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response, tumor volume and sites, and even invasion
depth [37–42]. The higher optimal resection rate and
chemotherapy response rate accompany by the dis-
appearance of ascites may explain the association be-
tween ascites regression and prognosis.
Up to present, there were four randomized clinical tri-
als comparing PDS and NAC followed by IDS for
women with advanced ovarian cancer [36, 43–45]. These
trials demonstrated that NAC/IDS was noninferior to
PDS with respect to PFS and OS and resulted in a lower
incidence of treatment-related morbidity and mortality.
In EORTC 55971 [36], residual tumor of 1 cm or less
was achieved in 42% of patients in the PDS arm and in
81% of patients in the NAC/IDS arm. Cytoreduction to
< =1 cm residual disease was achieved in 41% of patients
in the PDS arm and 73% of patients in the NAC/IDS
arm (p = 0.0001) in the CHORUS trial [43]. The SCOR-
PION [44, 46] trial found that complete cytoreduction
was achieved in 58% of women in the NAC/IDS arm
and 46% of women in the PDS arm, with a shorter me-
dian operative time in the NAC/IDS arm. In JCOG0602
[45], Optimal debulking proportions in NAC/IDS and
PDS were 82 and 37%, respectively. Most of HG-SOCs
are sensitive to platinum-based chemotherapy, and opti-
mal debulking proportions increased in patients who
underwent NAC. The rate of optimal cytoreduction in
our study is up to 80.6%, similar to existing trials. It is
very unlikely that an optimal surgical cytoreduction can
be achieved in all HG-SOC patients who underwent
NAC from literatures to the present study.
Fig. 1 ROC curve for the outcome of interval cytoreduction surgery by preoperative serum CA-125 level, decreasing kinetics, and ascites volume
Table 3 Survival-related characteristics in advanced HG-SOCs who underwent NAC/IDS
Variable Univariate Multivariate
PFS OS PFS OS
FIGO stage
IV 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
IIIc 3.03 (0.35–13.66) 4.24 (0.52–6.95) 2.28 (0.30–4.10) 3.57 (0.48–6.46)
Ascites
> =500 ml 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
< 500 ml 1.82 (1.45–2.85) 1.90 (1.56–2.98) 2.05 (1.40–2.95) 2.02 (1.66–4.08)
Outcome of surgery
Suboptimal 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Optimal 1.52 (1.15–2.42) 1.66 (1.22–2.50) 1.93 (1.75–2.84) 2.20 (1.40–4.24)
Tumor sites
> 3 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
< = 3 1.32 (1.12–1.80) 1.49 (1.25–2.25) 1.26 (0.94–1.74) 1.40 (0.85–2.04)
Baseline CA-125 1.02 (1.01–1.08) 1.03 (1.01–1.08) 1.02 (0.97–1.07) 1.02 (0.98–1.06)
Preoperative CA-125 1.01 (1.00–1.04) 1.01 (1.00–1.04) 1.02 (0.96–1.05) 1.02 (0.96–1.05)
CA-125 decreasing kinetics 1.02 (1.00–1.04) 1.02 (1.00–1.04) 1.01 (1.00–1.04) 1.01 (1.00–1.05)
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This retrospective analysis has several limitations.
Firstly, unavoidable selection biases are inherent to its
design. Given the long durations of our study, the influ-
ence of the administration change such as the emer-
gence of new chemotherapy and molecular target
agents, the improvement of disease evaluate strategy is
difficult to exclude. The relatively severe recruited cri-
teria may partly eliminate the influence of selected fac-
tors. Secondly, the absence of unified recruited standard
for NAC/IDS and limited sample size also causes bias
though MDT was set to indentify cases. Last but not
least, recruited advanced stage HG-SOCs who under-
went NAC/IDS were relatively older and comparatively
frail. It cannot be translated to all EOCs directly until
studies with accurate inclusion and exclusion criteria are
available. Overall, given the selection bias of this non-
blinded study, the application of these favorable out-
comes to all epithelial ovarian carcinoma patients should
be with caution.
Conclusions
Our study supports the emerging evidence that ascites
regression in advanced HG-SOCs is a predictor of opti-
mal IDS. Ascites regression should be considered as an
independent prognostic factor for both OS and PFS.
Fig. 2 Ascites regression (a, b) is associated with longer OS and PFS in patients with advanced stage HG-SOC who underwent NAC/IDS
Fig. 3 Higher CA-125 decreasing kinetics (a, b) is associated with longer OS and PFS in patients with advanced HG-SOCs who underwent NAC/IDS
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